In order to replicate lightning, Stanley Miller, a graduate student at the University of Chicago, set up a flask in 1953, filled it with methane, ammonia, hydrogen, and water—the approximate chemical composition that scientists thought existed on the early Earth—and passed an electric current through it.
A week later, amino acids were produced by the mixture. From nothing recognizable as life, the components of life had come together. Miller had created something in a laboratory that, in theory, seemed to be at the very limit of what science was meant to accomplish. The experiment gained notoriety. Then, for the better part of seven decades, life itself remained obstinately unattainable for anyone attempting to construct it instead of studying it.
| Field | Details |
|---|---|
| Field Name | Synthetic Biology (SynBio) |
| Term First Used | Stéphane Leduc, 1910 (Théorie physico-chimique de la vie) |
| Modern Definition Emergence | 1980 — Barbara Hobom applied term to genetically modified bacteria |
| Key Milestone | 2010 — First synthetic bacterial genome (M. mycoides JCVI-syn1.0) published in Science |
| CRISPR-Cas9 Published | 2012 — Charpentier & Doudna labs, Science |
| First Computer-Designed Genome | 2019 — ETH Zurich; Caulobacter ethensis-2.0 |
| First Xenobot Created | 2020 — AI-designed programmable organism from frog cells |
| Xenobot Self-Replication | 2021 — xenobots demonstrated self-replication capability |
| Global Industry Size (2016) | 350+ companies across 40 countries; estimated market ~$3.9 billion |
| Key Applications | Cancer treatment, drug delivery, biosensors, agriculture, biofuels, environmental cleanup |
| Reference Website | NIH – National Human Genome Research Institute: Synthetic Biology |
If you sit with it honestly, the acceleration at which that distance has been closing is still a little hard to fully comprehend. A bacterial cell whose entire genetic instruction set had been chemically assembled from scratch and transplanted into a living cell, effectively rebooting it as a new organism, was the first organism controlled by a synthetic genome, according to a 2010 paper published in Science by researchers at the J. Craig Venter Institute.
The first fully computer-designed bacterial genome was reported in 2019 by a team at ETH Zurich in Switzerland. Then, in 2020, scientists used artificial intelligence to create a xenobot, a programmable living thing made of frog cells that moved, reacted to its surroundings, and exhibited behaviors that were unrelated to anything found in the biological record. Those xenobots showed signs of self-replication a year later, assembling new copies of themselves by collecting loose cells in a dish. Not in a symbolic sense. In actuality. The field that began with the study of life is now actually and quantitatively creating it.
In order to treat living systems the way engineers treat machines—that is, as things that can be designed, assembled from standardized parts, optimized, and rebuilt when the design needs to be changed—synthetic biology, as a formal discipline, simultaneously draws from an astounding array of sources, including molecular biology, genetic engineering, computer science, chemical engineering, and evolutionary theory.
There is more to the engineering analogy than just metaphor. When describing biological systems, researchers in this field actually use the language of circuits, modules, and components. Since the early 2000s, they have been creating actual standardized DNA components, known as BioBricks, which were created at MIT in 2003 and can be assembled like Lego pieces to create organisms with specific functions.
Over 350 businesses in 40 countries were developing synthetic biology applications by 2016, with a combined estimated market value of about $3.9 billion. Since then, that number has increased significantly due to declining costs for DNA synthesis and sequencing, which have reduced the technical barriers to entry to almost nothing.
The scope of ambition and the accuracy of the instruments are what distinguish the current era from previous genetic engineering waves. The CRISPR-Cas9 gene editing system, which was developed by Charpentier and Doudna’s labs and published in Science in 2012, made targeted editing of existing genomes orders of magnitude faster and less expensive. Its creators were awarded the Nobel Prize and successfully democratized a capability that had previously required costly specialized equipment and years of technical training.
However, CRISPR modifies already-existing genomes. Instead of editing, the more radical subfield of synthetic biology writes. In order to create a viable bacterial variant that encodes amino acids in a manner not found in any natural organism, researchers have reduced the natural genetic code of E. coli from 64 codons to 59. This resulted in something that had truly never existed before in 2019; it was structurally distinct from the life that evolution produced, without being altered or adapted. It’s difficult not to feel a mixture of awe and vertigo when you look at that.
The real-world uses that are being explored are significant and diverse. Synthetic biology is being used in medicine to create bacteria that can identify cancer cells within the body and initiate therapeutic reactions right at the tumor site—a biosensor and drug delivery system functioning inside a living individual. Engineered microbes are being used in drug development pipelines to create compounds that would otherwise need costly and complicated chemical synthesis.
Through modified metabolic pathways, microbial cells are now producing artemisinin, a vital antimalarial compound that was previously hard to obtain in adequate amounts. Applications in agriculture include crops designed to directly fix nitrogen from the atmosphere, which could lessen the world’s reliance on synthetic fertilizers, whose production is expensive and energy-intensive. In other words, the field’s scope extends beyond labs seeking results that can be published. It is expanding into industries.
The field is aware of the ethical issues that surround all of this. The creation of organisms with unique genetic architectures raises concerns about what would happen if they were to unintentionally or through a series of unanticipated events escape controlled environments. Theoretically, a synthetic organism created to need non-natural materials to survive might be constrained by that dependence and unable to procreate outside of a lab. Or it may not be.
For organisms whose genetic code is created from scratch on a computer, it is still unclear whether the legal frameworks governing genetic engineering—the majority of which were created with simpler modifications in mind—are sufficient. According to the history of technology, the gap between a field’s capabilities and what governance structures can manage tends to be greatest during times of rapid advancement. Right now, synthetic biology might be in that gap.
Observing this field from the outside, it seems that the true narrative is not any one experiment or organism, but rather the gradual change in the definition of “life” that is being asked. Life was something that existed and was studied for the majority of human history; it was fundamentally given rather than created, though it was occasionally altered on the periphery.
Slowly but surely, synthetic biology is changing that presumption. The self-replicating xenobots in a Vermont lab are not organisms found in nature. Furthermore, they are not robots. They belong to a category that was unnamed prior to their creation. That’s where the field is going, not toward improved versions of already-existing organisms, but toward evolving, self-sustaining, organized matter that nature was never able to produce. Depending on the day and the particular application, that may be thrilling, frightening, or both. However, it is occurring and progressing more quickly than the majority of public discourse has acknowledged.
